Novo Nordisk launches Wegovy in India to challenge Lilly’s Mounjaro

On June 24, 2025, Danish pharmaceutical firm Novo Nordisk officially introduced its once-weekly injectable weight‑loss drug, Wegovy (semaglutide), to the Indian market  . Available in five dosage strengths (0.25 mg to 2.4 mg) via a user-friendly pen device, Wegovy is priced competitively—₹4,366 per weekly dose for lower strengths (monthly ₹17,345) and up to ₹26,015 for the top dose—mirroring the pricing of rival Mounjaro, launched by Eli Lilly in March  . Clinical evidence suggests Wegovy can reduce body weight by approximately 15%, with up to 20% loss in one-third of users, plus cardiovascular benefits—though Mounjaro has shown slightly higher average losses (about 23%)  . Novo Nordisk projects a sales target of $1 billion (₹8,600 crore) in India within five to seven years and says it expects no supply constraints  . Analysts predict steep price drops (60–90%) once semaglutide generics launch after patent expiry in 2026  .